AlleyCorp is the company-building machine behind some of New York's most iconic startups. Founded as a family office in 2007 by serial entrepreneur Kevin Ryan — often called the "Godfather of NYC Tech" — the firm both incubates companies from scratch and invests in early-stage startups, and has the track record to show for it: the AlleyCorp team incubated MongoDB, Gilt Groupe, Business Insider and Zola.
The firm's model is distinctive. AlleyCorp originates ideas, hires the teams, provides initial funding, launches the companies and maintains leadership through their lifecycles — true venture-studio company building. Alongside that, it actively invests across pre-seed, seed and Series A in dedicated verticals: Diversified Technology, Healthcare, Robotics and Social Impact. The firm makes roughly 20–30 new investments a year plus 5–8 incubations.
Capital has scaled dramatically. AlleyCorp took on outside investors for the first time in 2024 with a $250 million fund, then closed a $335 million second institutional fund in July 2026, reported by Fortune. The firm is reported to hold eight unicorns in its portfolio, including Rogo, ShopMy, Valar Atomics and Thyme Care — with sources citing a 60% all-time IRR on prior investments.
Incubated companies also include Nomad Health, Pearl Health and Transcend Therapeutics — the latter a psychedelics-based mental health company co-founded by Ryan that sold in June 2026 for $1.2 billion, a textbook example of AlleyCorp's willingness to bet on emerging categories before they are obvious.
Kevin Ryan remains founder and CEO, with the bench including practitioners who have run the firm's vertical efforts — such as Blake Mandell, who led AlleyCorp's frontier technology practice and co-founded Transcend, and Desiree Almodovar, a director who spearheaded the firm's Peerless Pitch initiative: a $1 million pitch competition launched with Management Leadership for Tomorrow to fund underrepresented founders, with talent, mentorship and Tech:NYC membership for the winner.
For founders, AlleyCorp offers something most VCs cannot: genuine company-building DNA. The firm invests at pre-revenue or minimal-revenue stages — Ryan has cited backing companies at $25 million valuations with $500,000 in revenue — across healthcare, deep tech and general technology. There is no standardised perks catalogue; the value-add is operators who have built companies themselves.
Why it matters for founders
AlleyCorp is the closest thing New York has to a founder factory: a team that has repeatedly turned raw ideas into category companies. If you're building in healthcare, robotics or deep tech at the earliest stage, few investors have actually sat in the founder chair as often as this team has.